Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
Status:
Completed
Trial end date:
2019-12-05
Target enrollment:
Participant gender:
Summary
This study employed a prospective, single-arm, global multi-center interventional open-label,
non-randomized design to identify and assess safety profile of the crushed deferasirox FCT
when administered up to 24 weeks in pediatric patients aged ≥2 to <6 years with transfusional
hemosiderosis. The study was designed to enroll a minimum of 40 patients. Forty-four patients
were treated and analyzed.